ArticlesDownstreamDownstreamEvents November 1, 2024 On-demand webinar: In silico process development for AAVs – Learn from MeiraGTx CytivaThe biotherapeutics pipeline is evolving and so are the tools to purify and manufacture therapeutic… Jeanne Linke
ArticlesDownstream December 15, 2023 A deep dive into optimizing AAV capture and polishing to maximize both yield and purity As demand for AAV vectors grows, so does the need for scalable and cost-efficient purification... admin-element
ArticlesBioPharma August 25, 2023 Balancing AAVs Versus LLVs Knowledge of adeno-associated variant's infection pathway is based on only a few serotypes. admin-element
ArticlesUpstream May 19, 2023 How to develop a scalable rAAV process Adeno-associated virus (AAV) is the most common vector for gene therapy, yet there’s much room… admin-element
Articles March 10, 2023 High-titer Vector Producing Cells Therapeutic biologics are thriving, according to Zhou Jiang, director Cell Culture Services at Cytiva. admin-element
ArticlesUpstream January 12, 2023 rAAV Production Using HEK293 Cell Line and Transfection Medium Improving the performance of a scalable AAV process in Xcellerex™ XDR-10 and XDR-200 bioreactor... admin-element
Articles October 21, 2021 Scalable AAV Production Process for Gene Therapy Viral vectors are often used for gene transfer of specific tissue- or cell-type modifications. admin-element
ArticlesDownstream August 30, 2021 How to Optimize and Scale Up AAV Production In this article from a roundtable discussion, four experts from academia and industry met to discuss... admin-element